308 related articles for article (PubMed ID: 10077623)
1. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
Overwijk WW; Lee DS; Surman DR; Irvine KR; Touloukian CE; Chan CC; Carroll MW; Moss B; Rosenberg SA; Restifo NP
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2982-7. PubMed ID: 10077623
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
[TBL] [Abstract][Full Text] [Related]
3. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo.
Bronte V; Apolloni E; Ronca R; Zamboni P; Overwijk WW; Surman DR; Restifo NP; Zanovello P
Cancer Res; 2000 Jan; 60(2):253-8. PubMed ID: 10667570
[TBL] [Abstract][Full Text] [Related]
4. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.
Hara I; Takechi Y; Houghton AN
J Exp Med; 1995 Nov; 182(5):1609-14. PubMed ID: 7595233
[TBL] [Abstract][Full Text] [Related]
5. Tumor immunity and autoimmunity induced by immunization with homologous DNA.
Weber LW; Bowne WB; Wolchok JD; Srinivasan R; Qin J; Moroi Y; Clynes R; Song P; Lewis JJ; Houghton AN
J Clin Invest; 1998 Sep; 102(6):1258-64. PubMed ID: 9739060
[TBL] [Abstract][Full Text] [Related]
6. Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo.
Steitz J; Brück J; Lenz J; Büchs S; Tüting T
J Invest Dermatol; 2005 Jan; 124(1):144-50. PubMed ID: 15654968
[TBL] [Abstract][Full Text] [Related]
7. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.
Overwijk WW; Tsung A; Irvine KR; Parkhurst MR; Goletz TJ; Tsung K; Carroll MW; Liu C; Moss B; Rosenberg SA; Restifo NP
J Exp Med; 1998 Jul; 188(2):277-86. PubMed ID: 9670040
[TBL] [Abstract][Full Text] [Related]
8. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
[TBL] [Abstract][Full Text] [Related]
9. Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".
Overwijk WW; Restifo NP
Crit Rev Immunol; 2000; 20(6):433-50. PubMed ID: 11396680
[TBL] [Abstract][Full Text] [Related]
10. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
[TBL] [Abstract][Full Text] [Related]
11. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response.
Ji Q; Gondek D; Hurwitz AA
J Immunol; 2005 Aug; 175(3):1456-63. PubMed ID: 16034082
[TBL] [Abstract][Full Text] [Related]
12. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
Yamanaka R; Xanthopoulos KG
DNA Cell Biol; 2005 May; 24(5):317-24. PubMed ID: 15869409
[TBL] [Abstract][Full Text] [Related]
13. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity.
Hawkins WG; Gold JS; Dyall R; Wolchok JD; Hoos A; Bowne WB; Srinivasan R; Houghton AN; Lewis JJ
Surgery; 2000 Aug; 128(2):273-80. PubMed ID: 10923004
[TBL] [Abstract][Full Text] [Related]
14. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.
Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C
J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311
[TBL] [Abstract][Full Text] [Related]
15. Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin.
Lane C; Leitch J; Tan X; Hadjati J; Bramson JL; Wan Y
Cancer Res; 2004 Feb; 64(4):1509-14. PubMed ID: 14973051
[TBL] [Abstract][Full Text] [Related]
16. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1.
Lang KS; Caroli CC; Muhm A; Wernet D; Moris A; Schittek B; Knauss-Scherwitz E; Stevanovic S; Rammensee HG; Garbe C
J Invest Dermatol; 2001 Jun; 116(6):891-7. PubMed ID: 11407977
[TBL] [Abstract][Full Text] [Related]
17. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitin-fusion degradation pathway plays an indispensable role in naked DNA vaccination with a chimeric gene encoding a syngeneic cytotoxic T lymphocyte epitope of melanocyte and green fluorescent protein.
Zhang M; Ishii K; Hisaeda H; Murata S; Chiba T; Tanaka K; Li Y; Obata C; Furue M; Himeno K
Immunology; 2004 Aug; 112(4):567-74. PubMed ID: 15270727
[TBL] [Abstract][Full Text] [Related]
19. Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization.
Surman DR; Irvine KR; Shulman EP; Allweis TM; Rosenberg SA; Restifo NP
J Immunol Methods; 1998 May; 214(1-2):51-62. PubMed ID: 9692858
[TBL] [Abstract][Full Text] [Related]
20. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
van Elsas A; Hurwitz AA; Allison JP
J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]